Reports FY24 revenue $6.171M, consensus $8.72M. “With my recent appointment as CEO of Arbutus, I am excited to lead the company into its next chapter,” said Lindsay Androski, President and CEO of Arbutus. “Along with Arbutus’ new directors, my focus is on evaluating strategies to accelerate the development and potential approval of imdusiran, alongside several subject matter experts being retained to assist with this evaluation. As part of this review, we have implemented a reduction in our workforce of 57%, retaining a core team well-positioned to advance imdusiran into a Phase 2b trial, and have taken additional related steps to improve our financial and operational efficiency. We will provide an update on our pipeline and development timeline upon completion of our review of our chronic hepatitis B virus programs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABUS:
- Strategic Legal Maneuvers Bolster Buy Rating for Arbutus Biopharma Amid Global Patent Challenges
- Genevant and Arbutus File Global Patent Lawsuits Against Moderna
- Genevant, Arbutus initiate patent infringement actions against Moderna
- Biotech Alert: Searches spiking for these stocks today
- Positive Outlook on Arbutus Biopharma Amid Strategic Focus and Legal Developments